Vera Therapeutics receives market perform rating with $34 target
VERA•Leerink Partners initiated coverage of Vera Therapeutics with a market perform rating and a $34 target price.
Related News
BMO cuts Alexandria Real Estate Equities to underperform from market perform, target to $41 from $48
ARE•
Globe Life Inc.: Wells Fargo raises target price to $191 from $190
GL•
Polar Power names Chris Mayer co-CEO in management restructuring
POLA•
Street View: Merck eye disease drug matches Roche's therapy in study, analysts cautious
RHHBY•
RLI Corp.: Wells Fargo cuts target price to $51 from $57
RLI•